Intriguingly, we find an enrichment of MAPK pathway mutations in advanced cancers and demonstrate that these alterations can promote a switch in pathway dependence from PI3K/AKT to MEK/ERK, lead to resistance to anti-HER2 therapies, and sensitize these cancers to MEK/ERK inhibitors. Here, ERBB2 is linked to cancer.